Background & Aims: Published studies suggest that children (<18 years) infected with COVID-19 are less likely to progress to the severe form of disease when compared to adults, however, scarce data are available on morbidity and mortality in immunocompromised children and adolescents. The aim of this study was to evaluate the outcomes of Pediatric Liver Transplant Recipients (PLTR) who were infected with COVID-19. Methods: Prospective longitudinal cohort study. Between 1st March 2020 and 31st October 2021 clinical, laboratory and evolution data from PLTR (<18 years) were collected in person or by remote telemedicine, who tested positive for COVID-19, for presenting symptoms suggestive of COVID-19 infection or positive epidemiological screening or for presenting positive in laboratory screening before procedure – incidental positive. Results: A total of 74 PLTR were diagnosed with COVID-19. The mean age was 8.2 years (SD 4.49) and 51.4% were girls. The prevalent indication for liver transplantation (LT) was biliary atresia 48 (64.8%) and in 69 (93.2%) patients LT was performed with a living donor. The mean time between LT and COVID-19 infection was 60 months (SD 57.7) and 5 (6.7%) patients became infected up to 3 months after LT, 2 in the early postoperative period. Most patients developed mild symptoms (66%) such as fever (25%), cough (20.2%) and runny nose (20.2%). Hospitalization of outpatients was necessary in 6 children (8.1%), all in hospital ward for suspected sepsis (1), respiratory distress (2), periorbital cellulitis requiring parenteral antibiotics (1), vomiting (1) and gum-stomatitis (1) both requiring hydroeletrolitic replacement. Only 1 child, previously admitted to hospital ward, required transfer to the ICU for respiratory support. The main comorbidities were atopic dermatitis in 5 patients (6.7%), asthma in 4 (5.4%), heart disease, neurological diseases and food allergy in 3(4%), none of which was related to the severity of presentation of COVID-19 infection. Baseline immunosuppression was based on tacrolimus, being associated with prednisone and mycophenolate in 28% and 13.7% respectively. Change in immunosuppression was required with mycophenolate discontinuation in 3 (4%) and a decrease tacrolimus level in 1 patient. Most patients had a good recovery, and only 1 child developed Multisystem Inflammatory Syndrome associated with COVID-19 infection. No child died in this study cohort. Conclusion: In pediatric population LT and immunosuppression cannot be considered independently as factors associated with the risk of severity and death due to COVID-19.